RecruitingPhase 2NCT06983028
Atacicept in Multiple Glomerular Diseases
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
Sponsor
Vera Therapeutics, Inc.
Enrollment
250 participants
Start Date
Jul 7, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Eligibility
Min Age: 2 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Atacicept for people with fsgs, igan, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAtacicept
Atacicept 150 mg SC QW via pre-filled syringe
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06983028
Related Trials
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT009779772 locations
Belimumab With Rituximab for Primary Membranous Nephropathy
NCT0394985520 locations
Immune System Related Kidney Disease
NCT000019791 location
From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP
NCT041740662 locations
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT0698935929 locations